Oncorus, Inc. Insider Trading for October 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Oncorus, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Oncorus, Inc. for October 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 08 2020 | ONCR | Oncorus, Inc. | Finer Mitchell H. | Director | Option Exercise | A | 1.81 | 42,970 | 77,776 | 42,970 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 700,453 | 0 | 0 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,525,348 | 0 | 0 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | P | 15.00 | 151,224 | 2,268,360 | 2,377,025 | 2.2 M to 2.4 M (+6.79 %) |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 700,453 | 0 | 2,225,801 | 1.5 M to 2.2 M (+45.92 %) |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 1,525,348 | 0 | 1,525,348 | 0 to 1.5 M |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 2,449,761 | 0 | 0 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 2,449,761 | 0 | 0 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 2,449,761 | 0 | 0 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 7,499,999 | 0 | 0 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 7,499,999 | 0 | 0 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | P | 15.00 | 109,612 | 1,644,180 | 312,282 | 202.7 K to 312.3 K (+54.08 %) |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | P | 15.00 | 445,194 | 6,677,910 | 1,268,344 | 823.2 K to 1.3 M (+54.08 %) |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | P | 15.00 | 445,194 | 6,677,910 | 1,268,344 | 823.2 K to 1.3 M (+54.08 %) |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 202,670 | 0 | 202,670 | 0 to 202.7 K |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 202,670 | 0 | 823,150 | 620.5 K to 823.2 K (+32.66 %) |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 202,670 | 0 | 823,150 | 620.5 K to 823.2 K (+32.66 %) |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 620,480 | 0 | 620,480 | 0 to 620.5 K |
| Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 620,480 | 0 | 620,480 | 0 to 620.5 K |
| Oct 05 2020 | ONCR | Oncorus, Inc. | Goldberg John Mayer | SVP, Clinical Devel ... | Option Exercise | A | 15.00 | 56,285 | 844,275 | 56,285 |